1. Scrip
  2. >>Drug Pricing

Novartis Teams With Pear Therapeutics In Neurological Digital Health Pact

 
• By Sten Stovall

Duo aims to get Pear's THRIVE digital therapeutic approved, and to develop a new application to treat MS patients, then seek validation in clinical studies.

Digital screen
Duo Will Develop Clinically-Validated Software Used for Schizophrenia and MS • Source: Shutterstock

Signalling its intent to embrace emerging digital technologies in the realm of neuro-degenerative and psychiatric diseases, Novartis AG has joined Pear Therapeutics in a collaboration on prescription software applications aimed at treating patients with schizophrenia and multiple sclerosis.Prescription digital therapeutics are clinically validated, FDA-cleared software applications that show safety and efficacy in randomized clinical trials to improve patient outcomes.

"We see digital therapeutics as a potentially vital part of future treatment models across a range of diseases with high...

More from Drug Pricing

Most Favored Nation Pricing: Trump Ups Pressure On Voluntary Action, Clarifies Demands

 
• By Sarah Karlin-Smith

The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By Kevin Grogan

François Roger believes fixing inefficiencies is more important than playing with pricing.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 
• By Andrew McConaghie

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By Kevin Grogan

The Swiss giant has been talking to the US government about selling medicines directly to patients.

More from Scrip

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.